Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Free Cash Flow (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Free Cash Flow for 7 consecutive years, with -$66.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 6.59% to -$66.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$234.3 million, a 13.02% decrease, with the full-year FY2025 number at -$234.3 million, down 13.02% from a year prior.
  • Free Cash Flow was -$66.9 million for Q4 2025 at Kymera Therapeutics, down from -$27.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$3.6 million in Q4 2023 to a low of -$79.6 million in Q1 2025.
  • A 5-year average of -$43.3 million and a median of -$40.3 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: surged 91.03% in 2023, then plummeted 1651.96% in 2024.
  • Kymera Therapeutics' Free Cash Flow stood at -$38.9 million in 2021, then decreased by 2.72% to -$39.9 million in 2022, then soared by 91.03% to -$3.6 million in 2023, then tumbled by 1651.96% to -$62.7 million in 2024, then decreased by 6.59% to -$66.9 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Free Cash Flow are -$66.9 million (Q4 2025), -$27.3 million (Q3 2025), and -$60.6 million (Q2 2025).